Chemische Bezeichnung: 0,0-dimethyl-(1hydroxy-2,2,2-trichloroethyl)-phosphonat.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abdi YA, Villén T (1991) Pharmacokinetics of metrifonate and its rearrangement product dichlorvos in whole blood. Pharmacol Toxicol 68: 137–139PubMedCrossRefGoogle Scholar
  2. Averbook BJ, Anderson RJ (1983) Electrophysiological changes associated with chronic administration of organophosphates. Arch Toxicol 52: 167–172PubMedCrossRefGoogle Scholar
  3. Bassant MH, Jazat-Poindessous F, Lamour Y (1996) Effects of metrifonate, a Cholinesterase inhibitor, on local cerebral glucose utilization in young and aged rats. J Cereb Blood Flow Metab 16: 1014–1025PubMedCrossRefGoogle Scholar
  4. Becker RE, Colliver J, Elble R, Feldman E, Giacobini E, Kumar V, Markwell S, Moriearty P, Parks R, Shillcutt SD, Unni L, Vicari S, Womack C, Zec RF (1990) Effects of metrifonate, a long-acting Cholinesterase inhibitor, in Alzheimer disease: report of an open trial. Drug Dev Res 19: 425–434CrossRefGoogle Scholar
  5. Becker RE, Moriearty P, Surbeck R, Unni L, Varney A, Vicary SA (1994) Second and third generation Cholinesterase inhibitors: clinical aspects. In: Giacobini E, Becker R (eds) Alzheimer disease: therapeutic strategies. Birkhäuser, Boston, pp 172–178Google Scholar
  6. Becker RE, Colliver JA, Markwell SJ, Moriearty PL, Unni LK, Vicari S (1996) Double-blind placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease. Alzheimer Dis Assoc Disord 10: 124–131PubMedCrossRefGoogle Scholar
  7. Bieber F, Creed Pettigrew L, Mas J, Schmitt F, Wermeling D (1995) Results of a phase IIa clinical trial with metrifonate. Psychopharmacol Bull 31: 554Google Scholar
  8. Blair D, Hoadley EC, Hutson DH (1975) The distribution of dichlorvos in the tissues of mammals after its inhalation or intravenous administration. Toxicol Appl Pharmacol 31: 243–253PubMedCrossRefGoogle Scholar
  9. Blair D, Dix KM, Hunt PF, Thorpe E, Stevenson DE, Walker AIT (1976) Dichlorvos — a 2-year inhalation carcinogenesis study in rats. Arch Toxicol 35: 281–294PubMedCrossRefGoogle Scholar
  10. Blokland A, Hinz V, Schmidt BH (1995) Effects of metrifonate and tacrine in the spatial morris task and modified irwin test: evaluation of the efficacy/safety profile in rats. Drug Dev Res 36: 166–177CrossRefGoogle Scholar
  11. Bolle WR (1956) Neguvon®: ein äuβerlich und innerlich anwendbares Insektizid, Larvizid und Ascarizid. Veterinärmedizinische Nachrichten 3: 155–172Google Scholar
  12. Cummings J, Bieber F, Mas J, Orazem J, Gulanski B (1997) Metrifonate in Alzheimer’s disease. Results of a dose-finding study. In: Iqbal K, Winblad B, Nishimura T, Takeda M, Wisniewski HM (eds) Alzheimer’s disease: biology, diagnosis and therapeutics. John Wiley and Sons, Chichester, pp 665–669Google Scholar
  13. Dubois KP, Cotter GJ (1955) Studies on the toxicity and mechanism of action of dipterex. Arch Industr Health 11: 53–60Google Scholar
  14. Edwards G, Breckenridge AM (1988) Clinical pharmakokinetics of antihelmintic drugs. Clin Pharmacokinet 15: 67–93PubMedGoogle Scholar
  15. Hallak M, Giacobini E (1989) Physostigmine, tacrine and metrifonate: the effect of multiple doses on acetylcholine metabolism in rat brain. Neuropharmacology 28: 199–206PubMedCrossRefGoogle Scholar
  16. Hinz VC, Grewig S, Schmidt BH (1996a) Metrifonate and dichlorvos: effects of a single oral administration on Cholinesterase activity in rat brain and blood. Neurochem Res 21: 339–345PubMedCrossRefGoogle Scholar
  17. Hinz VC, Grewig S, Schmidt BH (1996b) Metrifonate induces Cholinesterase inhibition exclusively via slow release of dichlorvos. Neurochem Res 21: 331–337PubMedCrossRefGoogle Scholar
  18. Hofer W (1981) Chemistry of metrifonate and dichlorvos. Acta Pharmacol Toxicol 49: 7–14CrossRefGoogle Scholar
  19. Holmstedt B, Nordgren I, Sandoz M, Sundwall A (1978) Metrifonate: summary of toxicological and pharmacological information available. Arch Toxicol 41: 3–29PubMedCrossRefGoogle Scholar
  20. Itoh A, Nitta A, Hirose M, Hasegawa T, Nabeshima T (1997a) Effects of metrifonate on impairment of learning and dysfunction of cholinergic neuronal system in basal fore-brain-lesioned rats. Behav Brain Res 83: 165–167PubMedCrossRefGoogle Scholar
  21. Itoh A, Nitta A, Katono Y, Usui M, Naruhashi K, Iida R, Hasegawa T, Nabeshima T (1997b) Effects of metrifonate on memory impairment and cholinergic dysfunction in rats. Eur J Pharmacol 322: 11–19PubMedCrossRefGoogle Scholar
  22. Jones KH, Sanderson DM, Noakes DN (1968) Acute toxicity data for pesticides. World Rev Pest Control 7: 135–143Google Scholar
  23. Kronforst-Collins MA, Moriearty PL, Ralph M, Becker RE, Schmidt B, Thompson LT, Disterhoft JF (1997) Metrifonate treatment enhances acquisition of eyeblink conditioning in aging rabbits. Pharmacol Biochem Behav 56: 103–110PubMedCrossRefGoogle Scholar
  24. Main AR (1979) Mode of action of anticholinesterases. Pharmacol Ther 6: 579–628CrossRefGoogle Scholar
  25. Metcalf RE, Fukuto RB, March RB (1959) Toxic action of dipterex® and DDVP in the house fly. J Econ Entomol 52: 44–49Google Scholar
  26. Mori F, Cuadra G, Giacobini E (1995) Metrifonate effects on acetylcholine and biogenic amines in rat cortex. Neurochem Res 20: 1081–1088PubMedCrossRefGoogle Scholar
  27. Moriearty PL, Womack CL, Dick BW, Colliver JA, Robbs RS (1991) Stability of peripheral hematological parameters after chronic acetylcholinesterase inhibition in man. Am J Hematol 37: 280–282PubMedCrossRefGoogle Scholar
  28. Morris J, Cyrus P, Orazem J, Mas J, Bieber F, Gulanski B (1997) Metrifonate: potential therapy for Alzheimer’s disease. News session — Poster, 49. Annu Meet Am Acad Neurol, Boston, Apr 1997Google Scholar
  29. Nordgren I, Holmstedt B, Bengtsson E, Finkel Y (1981) Plasma levels of metrifonate and dichlorvos during treatment of schistosomiasis with bilarcil. Acta Pharmacol Toxicol 48: 79–86Google Scholar
  30. Nordgren I, Karlen B, Kimland M (1992) Metrifonate and tacrine: a comperative study on their effect on acetylcholin dynamics in mouse brain. Pharmacol Toxicol 71: 236–240PubMedCrossRefGoogle Scholar
  31. Ogane N, Giacobini E, Messamore E (1992) Preferential inhibition of acetylcholinesterase molecular forms in rat brain. Neurochem Res 17: 489–495PubMedCrossRefGoogle Scholar
  32. Pacheco G, Palacios-Esquivel R, Moss DE (1995) Cholinesterase inhibitors proposed for treating dementia in Alzheimer’s disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase. J Pharmacol Exp Ther 274: 767–770PubMedGoogle Scholar
  33. Reiner E, Plestina R (1979) Regeneration of Cholinesterase activities in humane and rats after inhibition of 0,0-dimethy1-2,2-dichlorovinyl phosphate. Toxicol Appl Pharmacol 49: 451–454PubMedCrossRefGoogle Scholar
  34. Reynolds JEF (1989) Martindale: the extra pharmacopoeia, 29th ed. The Pharmaceutical Press, LondonGoogle Scholar
  35. Riekkinen P jr, Schmidt B, Stefanski R, Kuitunen J, Riekkinen M (1996) Metrifonate improves spatial navigation and avoidance behavior in scopolamine-treated, medial septum-lesioned and aged rats. Eur J Pharmacol 309: 121–130PubMedCrossRefGoogle Scholar
  36. Riekkinen M, Schmidt B, Riekkinen P jr (1997) Subchronic treatment increases the duration of the cognitive enhancement induced by metrifonate. Eur J Pharmacol 338: 105–110PubMedCrossRefGoogle Scholar
  37. Scali C, Giovannini MG, Bartolini L, Prosperi C, Hinz V, Schmidt BP, Pepeu G (1997) Effect of metrifonate on extracellular brain acetylcholine and object recognition in aged rats. Eur J Pharmacol 325: 173–180PubMedCrossRefGoogle Scholar
  38. Schmidt BH, Hinz VC, Blokland A, Van Der Staay F-J, Fanelli RJ (1996) Preclinical pharmacology of metrifonate: a promise for Alzheimer therapy. In: Becker R, Giacobini E (eds) Alzheimer disease: from molecular biology to therapy. Birkhäuser, Boston, pp 217–221Google Scholar
  39. Schmidt BH, Hinz VC, Van Der Staay F-J (1997) Cognition enhancement by metrifonate: evidence from animal studies. In: Iqbal K, Winblad B, Nishimura T, Takeda M, Wisniewski HM (eds) Alzheimer’s disease: biology, diagnosis and therapeutics. John Wiley and Sons, Chichester, pp 781–786Google Scholar
  40. Shekhar KC (1991) Schistosomiasis drug therapy and treatment considerations. Drugs 42: 379–405PubMedCrossRefGoogle Scholar
  41. Sherman M, Ross E (1961) Acute and subchronic toxicity of insecticides to chicks. Toxicol Appl Pharmacol 3: 521–533CrossRefGoogle Scholar
  42. Škrinjaric-Špoljar M, Simeon V, Reiner E (1973) Spontaneous reactivation and aging of di-methylphosphorylated acetylcholinesterase and cholinesterases. Biochim Biophys Acta 315: 363–369CrossRefGoogle Scholar
  43. Unni LK, Womack C, Hannant ME, Becker RE (1994) Pharmacokinetics and pharmacodynamics of metrifonate in humane. Meth Find Exp Clin Pharmacol 16: 285–289Google Scholar
  44. Van Der Staay FJ, Hinz VC, Schmidt BH (1996a) Effects of metrifonate, its transformation product dichlorvos, and other organophosphorous and reference Cholinesterase inhibitors on Morris water escape behavior in young-adult rats. J Pharmacol Exp Ther 278: 697–708PubMedGoogle Scholar
  45. Van Der Staay FJ, Hinz VC, Schmidt BH (1996b) Effects of metrifonate on escape and avoidance learning in young and aged rats. Behav Pharmacol 7: 56–64Google Scholar
  46. Villén T, Abdi YA, Erricsson Ö, Gustafsson LL, Sjöquist F (1990) Determination of metrifonate and dichlorvos in whole blood using gas chromatography and gas chromatography-mass spectrometry. J Chromatogr 529: 309–317PubMedCrossRefGoogle Scholar
  47. Witter RF, Gaines TB (1963) Relationship between depression of brain or plasma Cholinesterase and paralysis in chicken caused by certain organic phosphorous compounds. Biochem Pharmacol 12: 1377–1386PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1999

Authors and Affiliations

  • W. Retz
  • M. Rösler

There are no affiliations available

Personalised recommendations